Previous 10 | Next 10 |
The U.S. Food and Drug Administration granted fast track designation to Aura Biosciences' ( NASDAQ: AURA ) belzupacap sarotalocan (AU-011) to treat non-muscle invasive bladder cancer. The company said AU-011 is its first virus-like drug conjugate product candidate...
Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...
In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developi...
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan (AU-011),...
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in combin...
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor co...
Aura Biosciences press release (NASDAQ:AURA): Q1 GAAP EPS of -$0.44 misses by $0.01. Cash and cash equivalents and marketable securities totaling $133.3 million. Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 2024. Fo...
On Track to Meet Multiple Clinical Milestones for AU-011 in 2H 2022: Initiate Pivotal Trial in Choroidal Melanoma, Initiate Phase 1 Trial in Non-Muscle Invasive Bladder Cancer, and Submit IND for Choroidal Metastases Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage bio...
Preclinical studies support further development of AU-011 for choroidal metastasis Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today anno...
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura will present at the 2022...
News, Short Squeeze, Breakout and More Instantly...
Aura Biosciences Inc. Company Name:
AURA Stock Symbol:
NASDAQ Market:
Aura Biosciences Inc. Website:
2024-07-09 20:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
(NewsDirect) Aura Energy Ltd (ASX:AEE, AIM:AURA) MD Dave Woodall speaks with Proactive soon after announcing the company has raised A$10 million via a share placement at A$0.185 per share to advance development across the company’s project portfolio. The placement was supported by exis...
(NewsDirect) Aura Energy Limited (ASX: AEE, AIM: AURA) CEO Dave Woodall responds to a recent report that the Industry Committee of the Swedish parliament has voted to reject a number of private members’ motions supporting an immediate lifting of the ban on uranium mining in Sweden. He ...